Initial maintenance therapy with fluticasone propionate/ salmeterol combination product provides superior asthma control versus montelukast or fluticasone propionate alone Source: Eur Respir J 2002; 20: Suppl. 38, 386s Year: 2002
Comparison of fluticasone propionate plus theophylline with the salmeterol/fluticasone propionate combination in Japanese asthmatics Source: Eur Respir J 2005; 26: Suppl. 49, 44s Year: 2005
Efficacy of salmeterol/fluticasone propionate MDI versus higher dose fluticasone propionate in adolescent and adult asthmatics uncontrolled on fluticasone propionate alone Source: Eur Respir J 2003; 22: Suppl. 45, 438s Year: 2003
Timecourse of action of two inhaled corticosteroids, fluticasone propionate and budesonide Source: Eur Respir J 2002; 20: Suppl. 38, 308s Year: 2002
Once-daily, high-dose inhaled fluticasone propionate and salmeterol in patients having moderate asthma Source: Eur Respir J 2004; 24: Suppl. 48, 125s Year: 2004
Achievement of total control of asthma in clinical practice using the combination of inhaled salmeterol and fluticasone propionate Source: Eur Respir J 2006; 28: Suppl. 50, 616s Year: 2006
Combination therapy with salmeterol and fluticasone propionate (SFC) is more effective than salmeterol (SAL) alone in reducing exacerbations of COPD Source: Eur Respir J 2005; 26: Suppl. 49, 292s Year: 2005
Budesonide and formoterol in a single inhaler quickly gains asthma control compared with fluticasone propionate in mild asthma Source: Eur Respir J 2001; 18: Suppl. 33, 48s Year: 2001
Variable lipophilicity of budesonide: Comparison with fluticasone propionate, mometasone furoate, and ciclesonide Source: Eur Respir J 2003; 22: Suppl. 45, 33s Year: 2003
The potency ratio fluticasone propionate / budesonide Source: Eur Respir J 2003; 22: Suppl. 45, 33s Year: 2003
Efficacy and safety of ciclesonide compared with fluticasone propionate or budesonide in adolescent patients with persistent asthma Source: Eur Respir J 2007; 30: Suppl. 51, 458s Year: 2007
Scientific rationale for inhaled combination therapy with long-acting β2-agonists and corticosteroids Source: Eur Respir J 2002; 19: 182-191 Year: 2002
Bronchodilator effect of an inhaled combination therapy with salmeterol + fluticasone and formoterol + budesonide in patients with COPD Source: Eur Respir J 2002; 20: Suppl. 38, 386s Year: 2002
The effects of treatment with fluticasone propionate alone and combination with salmeterol on asthma control and airway inflammation Source: Eur Respir J 2003; 22: Suppl. 45, 287s Year: 2003
The effects of fluticasone propionate in asthmatic patients Source: Eur Respir J 2004; 24: Suppl. 48, 125s Year: 2004
Cost-effectiveness of budesonide and formoterol in a single inhaler compared to fluticasone in the treatment of asthma Source: Eur Respir J 2001; 18: Suppl. 33, 157s Year: 2001
Inhibition of allergen-iduced late asthmatic reaction by montelukast versus fluticasone propionate Source: Eur Respir J 2003; 22: Suppl. 45, 349s Year: 2003
QVAR pMDI is more cost-effective than fluticasone propionate (FP) or CFC-beclometasone dipropionate (BDP) PMDI in a real-life asthmatic population receiving an increase in ICS dose Source: Annual Congress 2009 - Sustainability in treatment of COPD patients according to economics and quality of care Year: 2009
Synergy with salmeterol and fluticasone propionate after administration from a single inhaler (Seretide™) Source: Eur Respir J 2001; 18: Suppl. 33, 176s Year: 2001
Fluticasone propionate/formoterol fumarate combination therapy is more effective than fluticasone propionate alone in the treatment of asthma Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010